According to the National Comprehensive Cancer Network Guidelines and Guidelines and Specifications for the Diagnosis and Treatment of Breast Cancer of the Chinese Anti-Cancer Association (2021 Edition),[16] among patients with locally advanced inoperable breast cancer, and those who subjectively strongly require breast conservation after the descending stage as well as those with Her2-positive or triple-negative breast cancer with a certain tumor load have indications for preoperative therapy. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.